Novartis | NVS - Gross Profit On Sales


Novartis reported $10.07B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Bausch Health Companies USD 2.08B 294M Jun/2026
Biogen USD 2.12B 307M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Canopy Growth CAD 8.26M 13.2M Mar/2026
Corcept Therapeutics USD 252.09M 90.07M Jun/2026
Drreddys Laboratories INR 43.04B 3.77B Mar/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novartis USD 10.07B 758M Mar/2026
Pacira USD 133.91M 7.27M Jun/2026
Perrigo USD 313.9M 11.6M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 136.19M 10.11M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
Sanofi EUR 8.11B 343M Mar/2026
Supernus Pharmaceuticals USD 160.06M 30.7M Jun/2026
Zoetis USD 1.76B 140M Jun/2026